This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Figure 5

IFN-γ and dual IFN-γ/IL-2 measured by ELIPSOT at Baseline and Day 29.

A sub-study of 22 individuals was conducted to evaluate whether VS411 induced an immunosuppressive effect on T lymphocytes. IFN-γ responses specific for Gag (A) and for Rev/Tat (B) and dual IFN-γ/IL-2 responses specific for Gag (C) and for Rev/Tat (D) at baseline and after 28 days treatment (Day 29) were measured by ELIPSOT (spots/million PBMCs). Horizontal red lines indicate mean values. There were no significant differences seen between pre- and post-therapy analyses suggesting that VS411 had no immunosuppressive effect on HIV-1-specific immune responses.